Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
21 Septiembre 2021 - 8:45AM
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF)
(CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company
focused on the research and development of therapeutics for medical
needs and rare disorders, announces today that AdvisorShares®
Investments LLC (“AdvisorShares”), a leading sponsor of actively
managed exchange-traded funds (ETFs) has included Revive
Therapeutics in the inaugural launch of its AdvisorShares
Psychedelics ETF (“PSIL”).
PSIL invests in the emerging psychedelic drugs
sector, offering exposure to biotechnology, pharmaceutical, and
life sciences companies leading the way in this nascent industry.
The ETF at launch includes 16 publicly listed companies offering
investors exposure to companies who are leading the way in the
emerging psychedelics space.“We are pleased to be included in the
inaugural launch of the PSIL ETF as it provides further validation
of our pharmaceutical psychedelics strategy in pursuing novel uses,
formulations and delivery forms of psilocybin for the treatment of
mental health and neurological conditions,” said Michael Frank, CEO
of the Company.PSIL commenced trading on September 16, 2021,
debuting on the New York Stock Exchange under ticker symbol (NYSE:
PSIL). The holdings of PSIL and its current portfolio weights are
regularly updated and available at
https://advisorshares.com/etfs/psil/.
About Revive Therapeutics
Ltd.
Revive is a life sciences company focused on the
research and development of therapeutics for infectious diseases
and rare disorders, and it is prioritizing drug development efforts
to take advantage of several regulatory incentives awarded by the
FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare
Pediatric Disease designations. Currently, the Company is exploring
the use of Bucillamine for the potential treatment of infectious
diseases, with an initial focus on severe influenza and COVID-19.
With its acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive’s cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and
to treat ischemia and reperfusion injury from organ
transplantation. For more information, visit
www.ReviveThera.com.
For more information, please contact:
Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel:
1 888 901
0036Email: mfrank@revivethera.comWebsite: www.revivethera.com
Neither the Canadian Securities Exchange nor its
Regulation Services Provider has reviewed or accepts responsibility
for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking
information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future
performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on Revive’s current belief or assumptions
as to the outcome and timing of such future events. Forward looking
information in this press release includes information with respect
to the the Company’s cannabinoids, psychedelics and infectious
diseases programs. Forward-looking information is based on
reasonable assumptions that have been made by Revive at the date of
the information and is subject to known and unknown risks,
uncertainties, and other factors that may cause actual results or
events to differ materially from those anticipated in the
forward-looking information. Given these risks, uncertainties and
assumptions, you should not unduly rely on these forward-looking
statements. The forward-looking information contained in this press
release is made as of the date hereof, and Revive is not obligated
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. The foregoing statements
expressly qualify any forward-looking information contained herein.
Reference is made to the risk factors disclosed under the heading
“Risk Factors” in the Company’s annual MD&A for the fiscal year
ended June 30, 2020, which has been filed on SEDAR and is available
under the Company’s profile at www.sedar.com.
AdvisorShares Tr (NYSE:PSIL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
AdvisorShares Tr (NYSE:PSIL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024